NCT00259298View on ClinicalTrials.gov

Evaluation of the Effects of Teriparatide on Skeleton Images in Postmenopausal Women With Osteoporosis

PHASE4CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

July 31, 2009

Study Completion Date

July 31, 2009

Conditions
Osteoporosis
Interventions
DRUG

teriparatide

Subcutaneous, 20 microgram (mcg)/day, 18 months

Trial Locations (1)

SE1 9RT

For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, London

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT00259298 - Evaluation of the Effects of Teriparatide on Skeleton Images in Postmenopausal Women With Osteoporosis | Biotech Hunter | Biotech Hunter